Corona Remedies: Business Overview & Financial Analysis
Corona Remedies is a fast-growing Indian pharmaceutical enterprise headquartered in Ahmedabad, Gujarat. Promoted by Dr. Kirtikumar Mehta and Nirav Mehta, the company operates primarily in the domestic formulations market, focusing on chronic and sub-chronic therapeutic segments. Corona Remedies manufactures and markets branded generic formulations across women's health, cardio-metabolic, gastrointestinal, pain management, and nutra-dermatology verticals. Operating WHO-GMP and ISO-certified manufacturing facilities in Solan (Himachal Pradesh) and Bavla (Gujarat), Corona Remedies distributes prescription drugs through an extensive doctor-coverage and stockist distribution network across India.
Therapeutic Segment Revenue Breakdown of Corona Remedies (FY26)
Corona Remedies structures its domestic formulation sales across high-growth chronic and specialized sub-chronic therapeutic categories.
- Women's Health & Gynaecology – 28.5% of Total Operating Revenue
- Cardiovascular & Anti-Diabetes – 24.2% of Total Operating Revenue
- Gastrointestinal & Hepatology – 18.5% of Total Operating Revenue
- Pain Management & Orthopaedics – 15.8% of Total Operating Revenue
- Nutra-Dermatology & Vitamins – 13.0% of Total Operating Revenue
- Total Consolidated Revenue from Operations (FY26) – Rs 1,285.40 crore (+16.8% YoY)
The Women's Health and Gynaecology division serves as the core revenue anchor, driven by specialized hormonal, fertility, and prenatal supplement brands. Cardio-metabolic and gastrointestinal categories provide expanding prescription volumes supported by chronic therapy refills.
Brand Portfolio & Market Position of Corona Remedies (FY26)
Corona Remedies manages a diversified portfolio of prescription drug brands holding leading market positions across Indian pharma categories.
- Top 10 Revenue Contributing Brands Share – ~42.0% of Total Formulation Revenue
- Total Active Commercial Formulations Portfolio – 250+ SKU offerings
- Total Doctor Coverage Footprint – 150,000+ prescribers covered across India
- Indian Pharmaceutical Market (IPM) Ranking – Top 40 Domestic Formulation Enterprise
The company's top 10 brands contribute over four-tenths of total turnover, led by flagship formulations in gynaecology and metabolic care. Active field force teams maintain regular prescribers' coverage across general practitioners, gynaecologists, cardiologists, and endocrinologists.
Distribution Network & Geographic Presence of Corona Remedies (FY26)
Corona Remedies delivers its pharmaceutical formulations across urban and Tier-2/3 retail pharmacy networks in India.
- Primary Stockists & Clearing Agents (CFAs) Base – 3,500+ primary stockists across India
- Retail Pharmacy Outlets Reach – 250,000+ retail chemist counters
- Regional Revenue Contribution – West India (32%), South India (28%), North India (25%), East India (15%)
- Field Force Strength – 3,200+ medical representatives and sales executives
Domestic sales account for over 95% of total turnover, supported by a 3,200+ strong sales force and 3,500+ primary stockists. Regional distribution is well-balanced across Western, Southern, and Northern Indian pharmaceutical markets.
Manufacturing Infrastructure & Facilities Network of Corona Remedies (FY26)
Corona Remedies operates state-of-the-art formulation processing units equipped with automated tableting, encapsulation, and liquid packaging lines.
- Operational Manufacturing Plant Locations – Solan (Himachal Pradesh) and Bavla (Ahmedabad, Gujarat)
- Annual Processing Capacity – 3.5+ billion tablets and capsules per annum
- Regulatory Certifications Base – WHO-GMP, ISO 9001:2015, and ISO 14001 certified sites
- Captive Analytical Testing R&D Units – In-house formulation development (F&D) centers in Ahmedabad
Manufacturing facilities in Himachal Pradesh and Gujarat process solid oral dosages, liquids, and soft-gelatin capsules under WHO-GMP compliance standards. In-house formulation development centers support product extensions and bio-equivalence trials.
Latest Quarterly Financial Performance of Corona Remedies (Q1 FY27)
Corona Remedies recorded strong top-line revenue expansion and operating profit growth during the first quarter of FY27.
- Consolidated Revenue from Operations – Rs 342.50 crore (+18.2% YoY)
- Consolidated Operating EBITDA – Rs 82.40 crore (+21.5% YoY)
- Operating EBITDA Margin – 24.05% (+65 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 52.80 crore (+24.2% YoY)
- Chronic Therapy Share in Quarterly Revenue – 58.5%
First-quarter operating revenue rose 18.2% year-on-year to Rs 342.50 crore, supported by volume gains across women's health and metabolic care brands. Consolidated Net Profit After Tax reached Rs 52.80 crore, while operating EBITDA margins expanded to 24.05%.
Consolidated Annual Financial Performance of Corona Remedies (FY26)
Corona Remedies achieved full-year turnover expansion and record net profitability for full financial year FY26.
- Full Year Consolidated Revenue from Operations – Rs 1,285.40 crore (+16.8% YoY)
- Full Year Operating EBITDA – Rs 301.20 crore (+19.5% YoY)
- Full Year Operating EBITDA Margin – 23.43% (+52 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 188.50 crore (+22.8% YoY)
- Return on Capital Employed (ROCE) – 22.5%
Full-year operating turnover crossed Rs 1,285 crore in FY26, as consolidated Net Profit After Tax expanded 22.8% to Rs 188.50 crore. Chronic prescription growth, new product launches, and operating leverage drove performance.
Capital Structure & Balance Sheet Health Ratios of Corona Remedies (Q1 FY27)
Corona Remedies maintains a low-debt financial structure backed by operating cash flow conversion and working capital discipline.
- Debt to Equity Ratio – Low Debt (0.15x)
- Total Cash, Bank Balances & Liquid Investments – Rs 210.00 crore
- Total Consolidated Net Worth Base – Rs 850.00 crore
- Return on Equity (ROE) – 22.2%
- Working Capital Cycle – 52 days
Total net worth expanded to Rs 850.00 crore as of June 30, 2026, with debt to equity holding comfortable at 0.15x. Operating cash flow conversion supported internal capital expenditure without reliance on external borrowing.
Capital Expenditure & Capacity Expansion Pipeline of Corona Remedies (FY27–FY28)
Corona Remedies executes capital allocation outlays to construct a new injectable facility and expand tableting capacity at Bavla.
- Total Planned Multi-Year Capex Outlay – Rs 150–180 crore over FY27–FY28
- Bavla Plant Expansion Outlay – Setting up a new high-speed tablet and capsule block at Bavla
- Sterile Liquid & Injectable Unit Outlay – Constructing a greenfield sterile injectable block for hospital supply
- Formulation Development (F&D) R&D Outlay – Expanding analytical testing infrastructure in Ahmedabad
- Funding Strategy – 100% funded through internal operational cash accruals and liquid reserves
Annual capital expenditure is budgeted at Rs 150–180 crore to add a sterile injectable block and expand tableting lines in Gujarat. Internal operational cash flows fund all planned facility modernizations without long-term debt additions.
Strategic Outlook & Management Commentary of Corona Remedies (Q1 FY27)
Management guidance outlines strategic priorities centered on chronic therapy scaling, sales force productivity, and new product launches.
- Management targets achieving a 18%–20% top-line revenue CAGR over the FY27–FY29 period.
- Operating EBITDA margins are guided to sustain within the 23.5%–25.0% corridor through operating leverage.
- Chronic and sub-chronic therapy share in total sales is targeted to reach 65% over the next 2 to 3 years.
- New product pipeline will focus on introducing 15–20 first-to-market combination formulations annually.
- Capital allocation strategy will prioritize funding internal brownfield expansions while maintaining low debt levels.
Management anticipates rising domestic chronic disease prevalence and prescription brand adoption to drive formulation sales. Operational focus centers on executing the Bavla facility expansion, increasing medical representative field productivity, and preserving balance sheet health.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Corona Remedies Q1 FY27 Consolidated Financial Results Disclosures (July/August 2026)
- Corona Remedies Q4 & Full Year FY26 Consolidated Financial Results Disclosures (May 2026)
- BSE Limited & National Stock Exchange of India (NSE) Corporate Filings for Corona Remedies
- Ticker Finology Corona Remedies Page
Disclaimer
The information presented above on Corona Remedies has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Corona Remedies page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.